Investigational drug · Phase 2
EVX-01
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Melanoma Stage IV, Unresectable Melanoma.
Phase 2Last checked: Nov 19, 2026Latest source record: Nov 4, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
1
Any phase or sponsor naming "EVX-01"
First trial start
2022
Sep 19, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "EVX-01", any sponsor or status.
Conditions studied
As listed on its trial records.
- Melanoma Stage IV
- Unresectable Melanoma
Largest trials
Live from ClinicalTrials.gov: studies naming "EVX-01" as an intervention, largest first.
Evaxion Biotech A/SIndustry
NCT05309421 · 17 participants · Start Sep 19, 2022 · Primary completion Apr 7, 2026
Drug: EVX-01; Pembrolizumab 25 MG/ML · For: Melanoma Stage IV; Unresectable Melanoma
Sites: Wollstonecraft, Australia; Nedlands, Australia; Milan, Italy · 4 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Dose escalation study of a personalized peptide-based neoantigen vaccine (EVX-01) in patients with metastatic melanoma.
Mørk SK, Skadborg SK, Albieri B, et al. · J Immunother Cancer 2024
- KEYNOTE - D36: personalized immunotherapy with a neoepitope vaccine, EVX-01 and pembrolizumab in advanced melanoma.
Long GV, Ferrucci PF, Khattak A, et al. · Future Oncol 2022
- Personalized therapy with peptide-based neoantigen vaccine (EVX-01) including a novel adjuvant, CAF®09b, in patients with metastatic melanoma.
Mørk SK, Kadivar M, Bol KF, et al. · Oncoimmunology 2022
Also in development for Melanoma Stage IV
- L19TNFL19IL2, OnfekafuspPhase 310 trials
Philogen S.p.A. · Glioblastoma, Locally Advanced Basal Cell Carcinoma, Melanoma Stage III
- BCD-217Phase 32 trials
Biocad · Melanoma Stage III, Melanoma (Skin), Melanoma
- prolgolimabBCD-100, FortecaPhase 31 trial
Biocad · Melanoma, Melanoma (Skin), Melanoma Stage III
- DNA VaccinePhase 22 trials
NEC Bio B.V · Triple Negative Breast Cancer, Malignant Melanoma, Melanoma (Skin)
- KB707Phase 22 trials
Krystal Biotech, Inc. · Cancer, Melanoma Stage III, Melanoma Stage IV
- GIM-531Phase 21 trial
Georgiamune Inc · Melanoma Stage IV, Solid Tumor
- ST101Phase 21 trial
Sapience Therapeutics · Glioblastoma, Melanoma Stage IV, Breast Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.